Form 8-K - Current report:
SEC Accession No. 0001213900-24-099333
Filing Date
2024-11-18
Accepted
2024-11-18 07:01:10
Documents
15
Period of Report
2024-11-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221568-8k_aldeyra.htm   iXBRL 8-K 35752
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED NOVEMBER 18, 2024 ea022156801ex99-1_aldeyra.htm EX-99.1 14561
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3900
  Complete submission text file 0001213900-24-099333.txt   238915

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aldx-20241115.xsd EX-101.SCH 3012
5 XBRL LABEL FILE aldx-20241115_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE aldx-20241115_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0221568-8k_aldeyra_htm.xml XML 3688
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241469739
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)